Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention

References

• Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993; 71(2 Suppl)566–72
   PubMed Web of Science ®Google Scholar
• Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 1998; 105(5)493–9
   PubMedGoogle Scholar
• Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer. Study of two large midwestern kindreds. Arch Intern Med 1966; 117(2)206–12
   PubMedGoogle Scholar
• Lynch HT, Guirgis HA, Albert S, Brennan M, Lynch J, Kraft C, et al. Familial association of carcinoma of the breast and ovary. Surg Gynecol Obstet 1974; 138(5)717–24
   PubMedGoogle Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266(5182)66–71
   PubMed Web of Science ®Google Scholar
• Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378(6559)789–92
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62(3)676–89
   PubMed Web of Science ®Google Scholar
• Gayther SA, Russell P, Harrington P, Antoniou AC, Easton DF, Ponder BA. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet 1999; 65(4)1021–9
   PubMed Web of Science ®Google Scholar
• Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, et al. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients. Eur J Hum Genet 2001; 9(6)424–30
   PubMed Web of Science ®Google Scholar
• Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996; 56(16)3663–5
   PubMed Web of Science ®Google Scholar
• Dorum A, Hovig E, Tropé C, Inganas M, Møller P. Three percent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA. Eur J Cancer 1999; 35: 779–81
   PubMed Web of Science ®Google Scholar
• Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis-Kindblom JM, Nordling M, et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer 2001; 37(15)1904–9
   PubMed Web of Science ®Google Scholar
• Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 2004; 40(3)422–8
   PubMed Web of Science ®Google Scholar
• Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, et al. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet 2001; 38(6)361–8
   PubMed Web of Science ®Google Scholar
• Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336(16)1125–30
   PubMed Web of Science ®Google Scholar
• Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4(10)2433–7
   PubMed Web of Science ®Google Scholar
• Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer 2000; 36(10)1200–8
   PubMed Web of Science ®Google Scholar
• Smith SA, Richards WE, Caito K, Hanjani P, Markman M, DeGeest K, et al. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. Gynecol Oncol 2001; 83(3)586–92
   PubMed Web of Science ®Google Scholar
• Menkiszak J, Gronwald J, Gorski B, Jakubowska A, Huzarski T, Byrski T, et al. Hereditary ovarian cancer in Poland. Int J Cancer 2003; 106(6)942–5
   PubMed Web of Science ®Google Scholar
• Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998; 178(4)670–7
   PubMed Web of Science ®Google Scholar
• Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68(3)700–10
   PubMed Web of Science ®Google Scholar
• Liede A, Malik IA, Aziz Z, Rios Pd PL, Kwan E, Narod SA. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. Am J Hum Genet 2002; 71(3)595–606
   PubMed Web of Science ®Google Scholar
• Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, et al. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat 2002; 20(1)28–34
   PubMed Web of Science ®Google Scholar
• Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283(17)2260–65
   PubMed Web of Science ®Google Scholar
• Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66(4)1259–72
   PubMed Web of Science ®Google Scholar
• Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345(4)235–40
   PubMed Web of Science ®Google Scholar
• Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8(12)3776–81
   PubMed Web of Science ®Google Scholar
• Hirsh-Yechezkel G, Chetrit A, Lubin F, Friedman E, Peretz T, Gershoni R, et al. Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel. Gynecol Oncol 2003; 89(3)494–8
   PubMed Web of Science ®Google Scholar
• Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20(6)1480–90
   PubMed Web of Science ®Google Scholar
• Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110(5)683–6
   PubMed Web of Science ®Google Scholar
• Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004; 23(1)29–34
   PubMed Web of Science ®Google Scholar
• Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60(5)1059–67
   PubMed Web of Science ®Google Scholar
• Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996; 2(11)1179–83
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol 2000; 18(2)173–90
   PubMed Web of Science ®Google Scholar
• Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000; 16(2)69–74
   PubMed Web of Science ®Google Scholar
• Moller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, et al. The BRCA1 syndrome and other inherited breast or breast–ovarian cancers in a Norwegian prospective series. Eur J Cancer 2001; 37(8)1027–32
   PubMed Web of Science ®Google Scholar
• Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 1996; 58(2)271–80
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvaldason H, Tryggvadottir L, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352(9137)1337–9
   PubMed Web of Science ®Google Scholar
• Johannsson O, Ostermeyer EA, Hakansson S, Friedman LS, Johansson U, Sellberg G, et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 1996; 58(3)441–50
   PubMed Web of Science ®Google Scholar
• Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet 2000; 8(10)757–63
   PubMed Web of Science ®Google Scholar
• Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56(1)265–71
   PubMed Web of Science ®Google Scholar
• Narod SA, Goldgar D, Cannon-Albright L, Weber B, Moslehi R, Ives E, et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995; 64(6)394–8
   PubMed Web of Science ®Google Scholar
• Dorum A, Heimdal K, Hovig E, Inganas M, Moller P. Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am J Hum Genet 1999; 65(3)671–9
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336(20)1401–8
   PubMed Web of Science ®Google Scholar
• Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72(5)1117–30
   PubMed Web of Science ®Google Scholar
• Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997; 64(2)196–206
   PubMed Web of Science ®Google Scholar
• Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21(4)407–11
   PubMed Web of Science ®Google Scholar
• Ramus SJ, Pharoah PD, Harrington P, Pye C, Werness B, Bobrow L, et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003; 63(2)417–23
   PubMed Web of Science ®Google Scholar
• Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, et al. A genetic epidemiological study of carcinoma of the fallopian tube. Gynecol Oncol 2001; 80(3)341–5
   PubMed Web of Science ®Google Scholar
• Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335(19)1413–6
   PubMed Web of Science ®Google Scholar
• Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res 1999; 59(4)868–71
   PubMed Web of Science ®Google Scholar
• Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998; 16(2)397–404
   PubMed Web of Science ®Google Scholar
• Narod SA, Boyd J. Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 2002; 14(1)19–26
   PubMed Web of Science ®Google Scholar
• The American College of Medical Genetics, Policy Statement: Genetic susceptibility to breast and ovarian Cancer: Assessment, Counseling and Testing Guidelines, 1999. www.acmg.net (verified 10/20/04).
   Google Scholar
• Vahteristo P, Eerola H, Tamminen A, Blomquist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast–ovarian cancer families. Br J Cancer 2001; 84(5)704–8
   PubMed Web of Science ®Google Scholar
• Whittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US, case–control studies II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136: 1184–203
   PubMed Web of Science ®Google Scholar
• Rosenblatt KA, Thomas DB, Noonan EA. High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 1992; 28A(11)1872–6
   PubMed Web of Science ®Google Scholar
• Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, et al. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339(7)424–8
   PubMed Web of Science ®Google Scholar
• Modugno F, Moslehi R, Ness RB, Nelson DB, Belle S, Kant JA, et al. Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States). Cancer Causes Control 2003; 14(5)439–46
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27.
   PubMed Web of Science ®Google Scholar
• Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000; 284: 1791–8
   PubMed Web of Science ®Google Scholar
• Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet 2001; 357(9267)1467–70
   PubMed Web of Science ®Google Scholar
• Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol 2000; 18(9)1980–95
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346(21)1616–22
   PubMed Web of Science ®Google Scholar
• Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijer MJ, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90: 1492–7
   PubMed Web of Science ®Google Scholar
• Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, et al. Occult ovarian tumours in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000; 18(14)2728–32
   PubMed Web of Science ®Google Scholar
• Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001; 25(10)1283–9
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346(21)1609–15
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91(17)1475–9
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000; 355(9220)2015–20
   PubMed Web of Science ®Google Scholar
• Swisher EM, Babb S, Whelan A, Mutch DG, Rader JS. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction. J Reprod Med 2001; 46(2)87–94
   PubMed Web of Science ®Google Scholar
• Menon U, Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002; 16(4)469–82
   PubMed Web of Science ®Google Scholar
• Burke W, Daly M, Garber J, Botkin J, Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277(12)997–1003
   PubMed Web of Science ®Google Scholar
• Laframboise S, Nedelcu R, Murphy J, Cole DE, Rosen B. Use of CA-125 and ultrasound In high-risk women. Int J Gynecol Cancer 2002; 12(1)86–91
   PubMed Web of Science ®Google Scholar
• NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA 1995; 273((6)): 491–7.
   PubMed Web of Science ®Google Scholar